Alphabiome
Tel Aviv, Israel· Est.
AI platform that predicts treatment response by analyzing hidden microbiome genetic signals.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $8M
AI Company Overview
AI platform that predicts treatment response by analyzing hidden microbiome genetic signals.
Precision MedicineDrug Development
Technology Platform
Proprietary AI-driven, reference‑free microbiome analytics that decode trillions of DNA fragments to identify predictive genetic biomarkers.
Opportunities
Securing pharma collaborations to apply microbiome‑AI biomarkers across human therapeutic programs and expanding validation studies to clinical cohorts.
Risk Factors
Reliance on successful translation of animal‑model findings to humans, regulatory acceptance of microbiome‑based diagnostics, and competition from established microbiome analytics firms.
Competitive Landscape
Competes with companies like Viome, DayTwo, and Ginkgo Bioworks; differentiation lies in its reference‑free, deep‑learning approach that captures >99% of microbial genetic data.